Empagliflozin Superior to Placebo for Heart Failure
WEDNESDAY, Sept. 2, 2020 -- Among patients with heart failure, risk for cardiovascular death or hospitalization with heart failure is lower for those receiving empagliflozin compared with placebo, according to a study published online Aug. 29 in the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Empagliflozin | Heart | Heart Failure | Jardiance | Pharmaceuticals | Study